查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1750412

預測性基因檢測與消費者基因體學市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Predictive Genetic Testing and Consumer Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球預測性基因檢測和消費者基因體學市場價值74億美元，預計到2034年將以14%的複合年成長率成長，達到271億美元。這得歸功於消費者對個人化醫療日益成長的興趣、基因檢測技術的進步以及人們轉向主動預防性健康策略。直接面對消費者 (DTC) 的基因檢測使獲取基因資訊的管道更加民主化，使個人無需醫療保健提供者的參與即可探索其祖先、生活方式特徵和潛在的健康風險。

預測性基因檢測與消費者基因體學市場 - IMG1

技術突破，尤其是在新一代定序 (NGS) 和人工智慧驅動的基因組解讀方面，顯著提高了檢測精度並降低了成本，拓寬了消費者的可及性。基因檢測公司與醫療保健提供者之間的合作進一步促進了這些進步，促進了基因組資料與臨床護理的整合。隨著慢性病盛行率的上升，以及醫療保健領域擴大採用預測性和精準醫療，北美預計將在這一不斷變化的格局中繼續保持全球領先地位。直接面對消費者 (DTC) 的基因檢測應用日益廣泛，顯著影響了市場發展勢頭，使個人能夠立即獲得健康風險洞察、血統分析以及與生活方式相關的遺傳特徵。隨著精通科技且注重健康的人需求激增，這些服務正變得越來越主流。此外，政府透過各種措施和美國國立衛生研究院 (NIH) 等機構的研究資金的大力支持，為基因組工具的開發和應用奠定了堅實的基礎。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 74億美元
預測值 271億美元
複合年成長率 14%

預測性檢測領域在2024年引領市場，價值41億美元。這些檢測根據個體的基因組成評估其患有特定疾病或病症的可能性，從而實現早期干預和個人化醫療策略。癌症篩檢應用佔據了相當大的市場佔有率，利用基因分析檢測與各種癌症相關的突變，促進早期診斷和有針對性的預防措施。

2024年，DTC細分市場引領全球預測基因檢測與消費者基因體學市場，產值達43億美元，預計到2034年將達到145億美元，這得益於消費者無需醫療專業人員參與即可便捷地獲取基因洞察。對個人化健康和保健解決方案日益成長的需求，推動了DTC檢測服務的普及。這些檢測使個人能夠在家中舒適地探索自己的血統、生活方式特徵和潛在健康風險。憑藉方便用戶使用的平台和經濟高效的試劑盒，DTC公司正在推動已開發市場和新興市場的主流消費者參與。

2024年，北美預測性基因檢測和消費者基因組學市場佔據42%的市場佔有率，這得益於其完善的醫療基礎設施、基因技術的早期應用，以及向個人化和預防性醫療的強勁文化轉變。受消費者意識不斷增強、教育水平不斷提高以及數位化健康參與度不斷提升的推動，該地區的消費者擴大將基因組檢測作為日常健康保健實踐的一部分。

全球預測性基因檢測和消費者基因組學產業的主要參與者包括雅培實驗室、安捷倫科技、奧雅納工程公司、華大基因、伯樂實驗室、丹納赫、EasyDNA、羅氏製藥、Illumina、Myriad Genetics、凱傑、Quest Diagnostics、賽默飛世爾科技和Variantyx。預測性基因檢測和消費者基因組學市場中的公司採用各種策略來增強其市場影響力。這些策略包括：投資研發以提高檢測準確性並擴展服務範圍；與醫療保健提供者建立策略合作夥伴關係以將基因檢測整合到臨床實踐中；以及擴展直接面對消費者的服務以提高可及性。此外，公司還注重法規合規性，以贏得消費者信任並確保其檢測的可靠性。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 個人化醫療意識不斷增強
      • 基因定序技術進步
      • 消費者對血統和健康的興趣日益濃厚
    • 產業陷阱與挑戰
      • 關於基因資料的倫理和隱私問題
      • 測試技術成本高
  • 成長潛力分析
  • 監管格局
  • 川普政府關稅
    • 需求面影響（售價）
      • 價格傳導至終端市場
    • 受影響的主要公司
    • 策略產業反應
      • 供應鏈重組
      • 定價和產品策略
      • 政策參與
    • 展望與未來考慮
  • 未來市場趨勢
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：按測試類型，2021-2034

  • 主要趨勢
  • 預測測試
    • 遺傳易感性檢測
    • 預測診斷
    • 人口篩檢
  • 消費者基因體學
  • 健康基因組學
    • 海狸鼠遺傳學
    • 皮膚和代謝遺傳學
    • 其他健康基因組學

第6章：市場估計與預測：按應用，2021-2034

  • 主要趨勢
  • 癌症篩檢
  • 心血管篩檢
  • 肌肉骨骼篩檢
  • 糖尿病篩檢和監測
  • 帕金森/阿茲海默症篩檢
  • 其他應用

第7章：市場估計與預測：按設置，2021-2034

  • 主要趨勢
  • 直接面對消費者（DTC）
  • 醫院和診所
  • 診斷實驗室

第8章：市場估計與預測：按地區，2021-2034

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies
  • ARUP Laboratories
  • BGI Genomics
  • Bio-Rad Laboratories
  • Danaher
  • EasyDNA
  • F. Hoffmann-La Roche
  • Illumina
  • Myriad Genetics
  • QIAGEN
  • Quest Diagnostics
  • Thermo Fisher Scientific
  • Variantyx
簡介目錄
Product Code: 13757

The Global Predictive Genetic Testing and Consumer Genomics Market was valued at USD 7.4 billion in 2024 and is estimated to grow at a CAGR of 14% to reach USD 27.1 billion by 2034, attributed to heightened consumer interest in personalized healthcare, advancements in genetic testing technologies, and a shift towards proactive, preventative health strategies. Direct-to-consumer (DTC) genetic testing has democratized access to genetic information, allowing individuals to explore their ancestry, lifestyle traits, and potential health risks without healthcare provider involvement.

Predictive Genetic Testing and Consumer Genomics Market - IMG1

Technological breakthroughs, particularly in next-generation sequencing (NGS) and AI-powered genomic interpretation, have dramatically improved test precision and lowered costs, broadening consumer access. These advancements are further complemented by partnerships between genetic testing firms and healthcare providers, facilitating the integration of genomic data into clinical care. As the prevalence of chronic illnesses rises, and healthcare increasingly adopts predictive and precision medicine, North America is positioned to remain the global leader in this evolving landscape. The expanding use of direct-to-consumer (DTC) genetic tests has significantly influenced market momentum, offering individuals immediate access to health risk insights, ancestry breakdowns, and lifestyle-related genetic traits. With a surge in demand from a tech-savvy and health-conscious population, these offerings are becoming more mainstream. Additionally, strong governmental backing through initiatives and research funding from institutions like the NIH has created a robust foundation for the development and application of genomic tools.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$7.4 Billion
Forecast Value$27.1 Billion
CAGR14%

The predictive testing segment led the market in 2024, valued at USD 4.1 billion. These tests assess the likelihood of individuals developing specific diseases or conditions based on their genetic makeup, enabling early intervention and personalized healthcare strategies. The cancer screening application accounted for a significant market share, utilizing genetic analysis to detect mutations associated with various cancers, facilitating early diagnosis and targeted prevention measures.

The DTC segment led the global predictive genetic testing and consumer genomics market in 2024, generating USD 4.3 billion and is projected to reach USD 14.5 billion by 2034, driven by offering consumers convenient access to genetic insights without the involvement of healthcare professionals. The growing demand for personalized health and wellness solutions is fueling the adoption of DTC testing services. These tests empower individuals to explore their ancestry, lifestyle traits, and potential health risks from the comfort of their homes. With user-friendly platforms and cost-effective kits, DTC companies are driving mainstream consumer engagement across both developed and emerging markets.

North America Predictive Genetic Testing and Consumer Genomics Market held 42% share in 2024 driven by a sophisticated healthcare infrastructure, early adoption of genetic technologies, and a strong cultural shift toward personalized and preventative medicine. Consumers in the region are increasingly embracing genomic testing as part of routine health and wellness practices, spurred by growing awareness, higher education levels, and digital health engagement.

Key players in the Global Predictive Genetic Testing and Consumer Genomics Industry include Abbott Laboratories, Agilent Technologies, ARUP Laboratories, BGI Genomics, Bio-Rad Laboratories, Danaher, EasyDNA, F. Hoffmann-La Roche, Illumina, Myriad Genetics, QIAGEN, Quest Diagnostics, Thermo Fisher Scientific, and Variantyx. Companies in the predictive genetic testing and consumer genomics market employ various strategies to strengthen their market presence. These include investing in research and development to enhance test accuracy and expand service offerings, forming strategic partnerships with healthcare providers to integrate genetic testing into clinical practices, and expanding direct-to-consumer services to increase accessibility. Additionally, companies are focusing on regulatory compliance to gain consumer trust and ensure the reliability of their tests.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising awareness about personalized medicine
      • 3.2.1.2 Technological advancements in genetic sequencing
      • 3.2.1.3 Growing consumer interest in ancestry and wellness
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Ethical and privacy concerns about genetic data
      • 3.2.2.2 High cost of testing technologies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Trump administration tariffs
    • 3.5.1 Demand-side impact (selling price)
      • 3.5.1.1 Price transmission to end markets
    • 3.5.2 Key companies impacted
    • 3.5.3 Strategic industry responses
      • 3.5.3.1 Supply chain reconfiguration
      • 3.5.3.2 Pricing and product strategies
      • 3.5.3.3 Policy engagement
    • 3.5.4 Outlook and future considerations
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021-2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Predictive testing
    • 5.2.1 Genetic susceptibility test
    • 5.2.2 Predictive diagnostics
    • 5.2.3 Population screening
  • 5.3 Consumer genomics
  • 5.4 Wellness genomics
    • 5.4.1 Nutria genetics
    • 5.4.2 Skin and metabolism genetics
    • 5.4.3 Other wellness genomics

Chapter 6 Market Estimates and Forecast, By Application, 2021-2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Cancer screening
  • 6.3 Cardiovascular screening
  • 6.4 Musculoskeletal screening
  • 6.5 Diabetic screening and monitoring
  • 6.6 Parkinsons/Alzheimer disease screening
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Setting, 2021-2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Direct-to-consumer (DTC)
  • 7.3 Hospitals and clinics
  • 7.4 Diagnostic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 MEA
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Agilent Technologies
  • 9.3 ARUP Laboratories
  • 9.4 BGI Genomics
  • 9.5 Bio-Rad Laboratories
  • 9.6 Danaher
  • 9.7 EasyDNA
  • 9.8 F. Hoffmann-La Roche
  • 9.9 Illumina
  • 9.10 Myriad Genetics
  • 9.11 QIAGEN
  • 9.12 Quest Diagnostics
  • 9.13 Thermo Fisher Scientific
  • 9.14 Variantyx